Key Takeaways
- Margin trough reached, recovery promised: Gross margins contracted 150 bps to 65.9% and EBITDA fell 14% YoY, but management called Q3 the last quarter of contraction and guided to pre-COVID EBITDA margins of ~27% for the full year.
- Demand still soft, recovery uncertain: Domestic volumes declined 3.9% on muted rural demand and a warmer winter; January demand remained sluggish and management admitted recovery "may take a while."
- International business resilient despite shocks: Grew 7% even as currency crises hit Bangladesh, Sri Lanka and Nepal, and an unplanned factory outage delayed shipments; back orders will be cleared by March.
- New Chief Growth Officer signals ambition: Giriraj Bagri, ex-CEO of ITC Foods and Raymond FMCG, joins as a full-time employee to hunt organic and inorganic growth beyond existing brands.
- What to watch next quarter: Whether gross margin expansion actually materializes in Q4, the pace of rural demand recovery post-budget, and the delivery of pending international orders.
Demand & Volume Performance
- Rural drag persisted: Domestic volumes declined 3.9% as rural markets stayed under pressure; low unit packs grew faster than larger packs, signalling down-trading visible across both rural and some urban markets.
- Winter failed to deliver: A warmer winter with very few severe-cold days hurt the winter portfolio; BoroPlus declined 3% and Navratna declined 6%, even though loading had proceeded normally from September through mid-December.
- December offered a glimmer: Demand saw a moderate rebound in December as inflation eased, but the improvement did not carry into January, leaving the recovery fragile and unconfirmed.
- Discretionary categories need macro help: Kesh King declined only 3% against a category decline of 10% per Nielsen, but management acknowledged that absolutely discretionary categories like Kesh King and Fair and Handsome require market improvement to return to growth.
Mohan Goenka: "The month of January, we haven't seen the kind of growth what we had seen in the last few weeks of December. So we will have to wait and watch for the complete recovery I think. It may take a while. I'm not too sure."
Margins & Cost Structure
- Q3 marked the margin bottom: Gross margins contracted 150 bps to 65.9% on inflationary pressure and an unfavourable portfolio mix from the prior year; EBITDA declined 14% YoY to ₹294 crores. Management explicitly stated this was the last quarter of contraction.
- Raw material relief arriving: Input cost pressure eased in Q3 relative to Q1 and Q2; from Q4 onwards, some gross margin benefits should begin to show, with YoY margins expected to improve.
- Full-year margin guidance intact: Management guided to full-year FY23 EBITDA margins at pre-COVID levels of around 27% for the core business, excluding The Man Company subsidiary.
- FY24 cost outlook optimistic: Management is "very hopeful" there will be no cost pressure next year, though budgets are still being finalized and formal guidance will follow.
- Project Khoj delivering efficiency: All action standards set at the year's start are being realized: cost-to-sales improved, the current network was optimized, and some subsidy costs were saved versus the past. Investments will continue because KPIs are being met.
Mohan Goenka: "In line with our guidance shared in the last con call, we believe this would be the last quarter for margin contraction."
International Business
- Growth despite multiple crises: International business grew 7% YoY, absorbing currency depreciation in Bangladesh, an economic crisis in Sri Lanka, forex and liquidity stress in Nepal, and ongoing political conflict in CIS countries.
- One factory outage, one brand hit: Growth was dented by lost shipments from one market where unplanned factory maintenance prevented supply; every other brand delivered growth. BoroPlus performed decently in Russia, CIS and Bangladesh.
- Back orders clearing by March: Pending orders from the factory disruption will be delivered between January and March, with most completed by fiscal year-end. Management expects the international business to remain on track for double-digit growth in coming quarters.
- Currency headwinds to persist: Depreciation in Sri Lanka, a sharp tanking in Bangladesh post-September, and depreciation against the Chinese currency created pressure that will take some time to work through.
Vivek Dhir: "Every brand in quarter 3 has delivered a growth except one brand, where we had some unplanned maintenance in the factory and we couldn't supply those goods when this happened. And those standing orders will be delivered in this quarter."
Strategic Initiatives & Portfolio Moves
- Chief Growth Officer appointed: Giriraj Bagri, previously CEO of Raymond FMCG and ITC Foods division, has joined as a full-time employee in a newly created role. His mandate spans organic and inorganic growth identification, digital strategy, and new start-up ideas, covering everything outside existing brands.
- D2C and healthcare pipeline building: New brands were launched in the D2C space over the last 3 to 6 months; a strong pipeline of NPD launches is planned for coming quarters across both D2C and traditional trade in OTC and the Medical business. Two new Avaleha products launched recently have performed well.
- Digital-first investments promising: Management expressed satisfaction with the experience of its four invested digital-first companies so far, calling all of them "very promising." The company continues to evaluate start-up opportunities for strategic investment.
- Omnichannel foundation being laid: D2C and e-commerce are expected to play an important role in future growth strategy; the company is building its presence through strategic investments in new-age companies.
- Rural distribution holding flat: Despite headwinds, the 9-month rural channel growth through the sub-stockist network is flat, indicating the distribution infrastructure is being maintained through the downturn.
FY24 Growth Outlook
- Double-digit growth expected: Management is "very hopeful" of at least 10% to 12% growth from most of the product range in FY24, even without factoring in market improvement, citing a favourable base in Healthcare and Pain Management.
- Discretionary recovery is the condition: For absolutely discretionary categories like Kesh King and Fair and Handsome, double-digit growth is contingent on market improvement; other categories are expected to grow even without a macro recovery. A good winter or summer would accelerate Navratna or BoroPlus.
- Healthcare acceleration from Q1: After Q4, when the high base effect wears off, Healthcare growth is expected to accelerate from Q1 onwards, driven by NPD and other initiatives. The market is expected to return to pre-COVID purchase levels with no external environmental factors seen impacting health supplement demand.
- More aggressive marketing planned: Corrective measures are planned across brands due to muted demand; raw material price correction will enable a more aggressive marketing strategy. Expansion in Project Khoj, rural distribution, e-commerce and modern trade will continue, alongside a rollout of new digital-first brands.
Mohan Goenka: "We are very hopeful that next year we are definitely going to see at least 10% to 12% growth, is what we should expect from most of the product range. Of course, the market sentiments have to improve. But even though, not considering the market, I think we should grow at double-digit numbers."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Gross margin expansion | YoY gross margins to improve from Q4 as raw material pressure eases | Q4 FY23 onwards |
| Full-year EBITDA margin | Core business EBITDA margin at pre-COVID level of ~27% | FY23 |
| International back orders | Pending orders from factory outage to be delivered; most completed | By March 2023 |
| Healthcare growth acceleration | Growth to pick up once high base effect wears out, driven by NPD | Q1 FY24 onwards |
| FY24 revenue growth | At least 10% to 12% growth from most of the product range | FY24 |
| MAT credit availability | MAT credit to continue, keeping tax rate at roughly 10% to 12% | FY24 |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Net sales | ₹975 cr, grew 2% YoY; 3-year CAGR of 7% |
| Revenues | ₹983 cr, grew 1% YoY |
| Domestic business growth | 1% YoY; 3-year CAGR of 6% |
| Domestic volumes | -3.9% YoY |
| International business growth | 7% YoY; 3-year CAGR of 13% |
| Gross margin | 65.9%, contracted 150 bps YoY |
| EBITDA | ₹294 cr, declined 14% YoY |
| Profit after tax | ₹237 cr, grew 8% YoY |
| Core business EBITDA margin guidance (FY23) | ~27%, excluding The Man Company |
| Tax rate guidance | 10% to 12%, considering MAT credit |
| Employee cost | ₹93 cr in Q3; expected regular run-rate ~₹90 cr per quarter |
| E-commerce contribution to domestic revenues | 7.9%, up 260 bps YoY |
| Modern trade contribution to domestic revenues | 10.5%, up 200 bps YoY |
| Modern trade + e-commerce combined contribution | 18.4% of domestic revenues, vs 13.8% in Q3 last year |
| Modern trade growth | 20% YoY |
| E-commerce growth | 45% YoY |
| Healthcare range growth | 2% YoY; 3-year CAGR of 8% |
| 7 Oils in One growth | 5% YoY; 3-year CAGR of 13% |
| BoroPlus range growth | -3% YoY; 3-year CAGR of 5% |
| Pain Management range growth | -2% YoY; 3-year CAGR of 6% |
| Kesh King growth | -1% YoY; 3-year CAGR of 4% |
| Navratna growth | -6% YoY |
| Male Grooming range growth | -1% YoY; 3-year CAGR marginal |
| The Man Company contribution to net sales | 2.8% of overall net sales |
| NPDs contribution to domestic net sales | ~4% |
| New/digital-first launches share in modern trade & e-commerce | 14% of sales in those channels |
| OTC to Ethical mix ratio | ~2.5 : 1 |
| Project Khoj business generated (9M FY23) | ~₹67 cr till date; expected ~₹83–85 cr by year-end |
| Total rural cost (sub-stockist channel) | ~6% of sales; network cost up ~7.8% |
| International business growth (9M FY23) | Close to 20% |
| Second interim dividend | ₹4 per share (400%) |